Lucence Cancer Screening Services in Singapore

Cancer remains one of the leading causes of death worldwide, emphasizing the critical need for accurate and early detection methods. Traditional cancer screenings often rely on imaging, tissue biopsies, and established biomarkers like PSA (prostate-specific antigen) for prostate cancer or CA-125 for ovarian cancer. While these methods have their merits, they come with limitations such as invasiveness and low sensitivity during the early stages. This highlights the need for innovative approaches in cancer detection. Lucence cancer screening, a revolutionary liquid biopsy technology, offers a more accurate and non-invasive solution for early cancer detection.

What Is Lucence Cancer Screening?

Lucence specializes in liquid biopsy technology, which analyzes circulating tumor DNA (ctDNA) and other cancer-related markers in the blood. This technology can detect genetic mutations, epigenetic changes, and other molecular indicators of cancer, even in its earliest stages. Unlike traditional biopsies, which require invasive tissue samples, liquid biopsies only need a simple blood draw, making them a safer, faster, and more patient-friendly alternative.

Accuracy Compared to Traditional Cancer Markers

A key advantage of Lucence cancer screening is its superior accuracy compared to conventional cancer markers. While traditional markers can be helpful, they often lack the sensitivity and specificity necessary for early cancer detection. For example:

• PSA (Prostate Cancer): Elevated PSA levels may indicate prostate cancer, but can also be linked to benign conditions like prostatitis or benign prostatic hyperplasia (BPH), leading to false positives and unnecessary biopsies.
• CA-125 (Ovarian Cancer): While elevated CA-125 levels are associated with ovarian cancer, they can also occur due to non-cancerous conditions like endometriosis or pelvic inflammatory disease, reducing the marker’s specificity.
• CEA (Carcinoembryonic Antigen): Raised CEA levels can suggest cancers of the colon, pancreas, stomach, or breast. However, CEA can also be elevated in many benign conditions, such as cirrhosis or ulcerative colitis, making it less reliable for early detection.

These traditional markers are often not sufficient on their own for cancer diagnosis. They must be combined with biopsies and imaging to confirm the diagnosis, and false positives can lead to unnecessary anxiety and investigations.

In contrast, Lucence’s ctDNA analysis focuses on identifying cancer-specific genetic mutations and epigenetic markers, which are more directly associated with malignancy. Studies comparing Lucence technology to traditional methods show significantly higher sensitivity and specificity. For example, Lucence has demonstrated the ability to detect cancers at Stage I or II with sensitivity rates over 90% for certain types, compared to the 70-80% sensitivity typically seen with traditional biomarkers.